Improved Efficacy of Low-Dose Spironolactone and Metformin Combination Than Either Drug Alone in the Management of Women With Polycystic Ovary Syndrome: A Six-Month, Open-Label Randomized Study

In the September 2013 study, researchers found that a combination of low-dose spironolactone (50 mg/day) and metformin (1000 mg/day) was more effective than either drug alone in managing symptoms of Polycystic Ovary Syndrome (PCOS) in women. The six-month study included 198 women, with 169 completing the study. The combination therapy led to significant improvements in menstrual cycles, hirsutism (as measured by the Ferriman-Gallwey score), serum total testosterone levels, and insulin sensitivity without significant changes in body weight, BMI, waist-hip ratio, or blood pressure. The combination group also experienced better compliance and fewer adverse events. The study concluded that the combination of spironolactone and metformin offers superior clinical benefits for women with PCOS compared to monotherapy with either drug.